APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Uricase

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Uricase Market Outlook and Growth Opportunities 2026

27 December 2025199 pages

Choose your research edition.

Industry ResearchRecombinant Uricase Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Uricase Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Recombinant Uricase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Uricase Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Uricase Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Recombinant Uricase market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Uricase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Uricase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Uricase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Uricase market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Uricase market include Horizo​​n Therapeutics and Sanofi among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Uricase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Uricase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Uricase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Uricase market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Uricase Segment by Company

Horizo​​n Therapeutics

Sanofi

Recombinant Uricase Segment by Type

Rasburicase

Pegloticase

Other

Recombinant Uricase Segment by Application

Gout

Kidney Stones

Cancer

Other

Recombinant Uricase Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Uricase status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Uricase market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Uricase significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Uricase competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Uricase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Uricase and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Uricase.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Uricase market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Uricase industry.

Chapter 3: Detailed analysis of Recombinant Uricase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Uricase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Uricase in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Uricase Industry Trends Table 2. Recombinant Uricase Industry Drivers Table 3. Recombinant Uricase Industry Opportunities and Challenges Table 4. Recombinant Uricase Industry Restraints Table 5. Global Recombinant Uricase Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Uricase Revenue Share by Company (2021-2026) Table 7. Global Recombinant Uricase Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Recombinant Uricase Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Uricase Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Recombinant Uricase Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Uricase Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Uricase Company, Product Type & Application Table 13. Global Recombinant Uricase Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Uricase by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rasburicase Table 18. Significant Companies of Pegloticase Table 19. Significant Companies of Other Table 20. Global Recombinant Uricase Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Recombinant Uricase Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Recombinant Uricase Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Recombinant Uricase Sales Volume Share by Type (2021-2026) Table 24. Global Recombinant Uricase Sales Volume Share by Type (2027-2032) Table 25. Global Recombinant Uricase Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Recombinant Uricase Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Recombinant Uricase Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Recombinant Uricase Sales Value Share by Type (2021-2026) Table 29. Global Recombinant Uricase Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Gout Table 31. Significant Companies of Kidney Stones Table 32. Significant Companies of Cancer Table 33. Significant Companies of Other Table 34. Global Recombinant Uricase Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Recombinant Uricase Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Recombinant Uricase Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Recombinant Uricase Sales Volume Share by Application (2021-2026) Table 38. Global Recombinant Uricase Sales Volume Share by Application (2027-2032) Table 39. Global Recombinant Uricase Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Recombinant Uricase Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Recombinant Uricase Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Recombinant Uricase Sales Value Share by Application (2021-2026) Table 43. Global Recombinant Uricase Sales Value Share by Application (2027-2032) Table 44. Global Recombinant Uricase Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Recombinant Uricase Sales by Region (2021-2026) & (K Units) Table 46. Global Recombinant Uricase Sales Market Share by Region (2021-2026) Table 47. Global Recombinant Uricase Sales by Region (2027-2032) & (K Units) Table 48. Global Recombinant Uricase Sales Market Share by Region (2027-2032) Table 49. Global Recombinant Uricase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Recombinant Uricase Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Recombinant Uricase Sales Value Share by Region (2021-2026) Table 52. Global Recombinant Uricase Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Recombinant Uricase Sales Value Share by Region (2027-2032) Table 54. Global Recombinant Uricase Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Recombinant Uricase Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Recombinant Uricase Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Recombinant Uricase Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Recombinant Uricase Sales by Country (2021-2026) & (K Units) Table 59. Global Recombinant Uricase Sales Market Share by Country (2021-2026) Table 60. Global Recombinant Uricase Sales by Country (2027-2032) & (K Units) Table 61. Global Recombinant Uricase Sales Market Share by Country (2027-2032) Table 62. Global Recombinant Uricase Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Recombinant Uricase Sales Value Market Share by Country (2021-2026) Table 64. Global Recombinant Uricase Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Recombinant Uricase Sales Value Market Share by Country (2027-2032) Table 66. Horizo​​n Therapeutics Company Information Table 67. Horizo​​n Therapeutics Business Overview Table 68. Horizo​​n Therapeutics Recombinant Uricase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Horizo​​n Therapeutics Recombinant Uricase Product Portfolio Table 70. Horizo​​n Therapeutics Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Recombinant Uricase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Recombinant Uricase Product Portfolio Table 75. Sanofi Recent Development Table 76. Key Raw Materials Table 77. Raw Materials Key Suppliers Table 78. Recombinant Uricase Distributors List Table 79. Recombinant Uricase Customers List Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Recombinant Uricase Product Image Figure 2. Global Recombinant Uricase Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Uricase Sales (2021-2032) & (K Units) Figure 5. Global Recombinant Uricase Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Recombinant Uricase Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rasburicase Image Figure 10. Pegloticase Image Figure 11. Other Image Figure 12. Global Recombinant Uricase Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Recombinant Uricase Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Recombinant Uricase Sales Volume Share by Type (2021-2032) Figure 15. Global Recombinant Uricase Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Recombinant Uricase Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Recombinant Uricase Sales Value Share by Type (2021-2032) Figure 18. Gout Image Figure 19. Kidney Stones Image Figure 20. Cancer Image Figure 21. Other Image Figure 22. Global Recombinant Uricase Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Recombinant Uricase Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Uricase Sales Volume Share by Application (2021-2032) Figure 25. Global Recombinant Uricase Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Recombinant Uricase Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Uricase Sales Value Share by Application (2021-2032) Figure 28. Global Recombinant Uricase Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Recombinant Uricase Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Recombinant Uricase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Recombinant Uricase Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 33. North America Recombinant Uricase Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Recombinant Uricase Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Recombinant Uricase Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 39. South America Recombinant Uricase Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Recombinant Uricase Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Recombinant Uricase Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Recombinant Uricase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Recombinant Uricase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Recombinant Uricase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Recombinant Uricase Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Recombinant Uricase Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Rasburicase
  • Pegloticase
  • Other
Applications
  • Gout
  • Kidney Stones
  • Cancer
  • Other
Companies covered
  • Horizo​​n Therapeutics
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Uricase Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Uricase Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Uricase Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Uricase Market Dynamics
  1. 2.1 Recombinant Uricase Industry Trends
  2. 2.2 Recombinant Uricase Industry Drivers
  3. 2.3 Recombinant Uricase Industry Opportunities and Challenges
  4. 2.4 Recombinant Uricase Industry Restraints
3 Recombinant Uricase Market by Company
  1. 3.1 Global Recombinant Uricase Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Uricase Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Uricase Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Uricase Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Uricase Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Uricase Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Uricase Company Product Type and Application
  8. 3.8 Global Recombinant Uricase Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Uricase Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Uricase Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Uricase Market by Type
  1. 4.1 Recombinant Uricase Type Introduction
  2. 4.1.1 Rasburicase
  3. 4.1.2 Pegloticase
  4. 4.1.3 Other
  5. 4.2 Global Recombinant Uricase Sales Volume by Type
  6. 4.2.1 Global Recombinant Uricase Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Recombinant Uricase Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Recombinant Uricase Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Recombinant Uricase Sales Value by Type
  10. 4.3.1 Global Recombinant Uricase Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Recombinant Uricase Sales Value by Type (2021-2032)
  12. 4.3.3 Global Recombinant Uricase Sales Value Share by Type (2021-2032)
5 Recombinant Uricase Market by Application
  1. 5.1 Recombinant Uricase Application Introduction
  2. 5.1.1 Gout
  3. 5.1.2 Kidney Stones
  4. 5.1.3 Cancer
  5. 5.1.4 Other
  6. 5.2 Global Recombinant Uricase Sales Volume by Application
  7. 5.2.1 Global Recombinant Uricase Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Uricase Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Recombinant Uricase Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Recombinant Uricase Sales Value by Application
  11. 5.3.1 Global Recombinant Uricase Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Recombinant Uricase Sales Value by Application (2021-2032)
  13. 5.3.3 Global Recombinant Uricase Sales Value Share by Application (2021-2032)
6 Recombinant Uricase Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Uricase Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Uricase Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Uricase Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Uricase Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Uricase Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Uricase Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Uricase Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Uricase Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Uricase Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Uricase Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Uricase Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Uricase Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Uricase Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Uricase Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Uricase Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Uricase Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Uricase Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Uricase Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Uricase Sales Value Share by Country, 2025 VS 2032
7 Recombinant Uricase Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Uricase Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Uricase Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Uricase Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Uricase Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Uricase Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Uricase Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Uricase Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Uricase Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Uricase Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Uricase Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Uricase Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Uricase Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Uricase Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Uricase Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Uricase Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Uricase Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Uricase Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Uricase Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Uricase Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Uricase Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Uricase Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Uricase Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Uricase Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Uricase Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Uricase Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Uricase Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Uricase Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Uricase Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Uricase Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Uricase Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Uricase Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Uricase Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Uricase Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Uricase Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Uricase Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Uricase Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Uricase Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Uricase Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Horizo​​n Therapeutics
  2. 8.1.1 Horizo​​n Therapeutics Company Information
  3. 8.1.2 Horizo​​n Therapeutics Business Overview
  4. 8.1.3 Horizo​​n Therapeutics Recombinant Uricase Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Horizo​​n Therapeutics Recombinant Uricase Product Portfolio
  6. 8.1.5 Horizo​​n Therapeutics Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Recombinant Uricase Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Recombinant Uricase Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Uricase Value Chain Analysis
  2. 9.1.1 Recombinant Uricase Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Uricase Sales Mode & Process
  6. 9.2 Recombinant Uricase Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Uricase Distributors
  9. 9.2.3 Recombinant Uricase Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst